CPT 82776: Galactose-1-Phosphate Uridyl Transferase (GALT) Measurement

CPT code 82776 designates laboratory measurement of the enzyme galactose-1-phosphate uridyl transferase (GALT), a key assay in newborn metabolic screening for galactosemia. Early identification of GALT deficiency is clinically important because untreated galactosemia can lead to severe neonatal complications. Nationally, newborn screening programs rely on standardized laboratory testing to detect inborn errors of metabolism, and CPT code 82776 captures this specific enzymatic analysis.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical role of the test, typical sites of service, and how the code is used in newborn screening workflows. The publication highlights common billing modifiers and service-line context where available, and summarizes payer coverage patterns and benchmarking where data exists. It also provides concise clinical context about galactosemia and why enzymatic confirmation complements newborn screening algorithms.

This summary is intended for billing managers, laboratory directors, and policy analysts seeking a national perspective on clinical function, coding placement, and payer engagement for the GALT enzyme assay captured by CPT code 82776. Data not available in the input is noted where applicable.

Billing Code Overview

CPT code 82776 reports measurement of the enzyme galactose-1-phosphate uridyl transferase (GALT), typically performed on a newborn blood spot specimen. The test detects GALT deficiency that prevents proper utilization of galactose and is used in newborn screening for galactosemia.

Service type: Laboratory diagnostic test (newborn metabolic screening)

Typical site of service: Hospital newborn nursery or outpatient newborn screening laboratory

Clinical Context

A newborn infant in the well-baby nursery has a routine newborn screening panel performed prior to discharge. A heel-stick blood spot is collected on filter paper within 24–48 hours of life. The laboratory performs measurement of the enzyme galactose-1-phosphate uridyl transferase using the dried blood spot to identify classic or variant galactosemia. Results are used to confirm biochemical enzyme deficiency when newborn screening flags elevated galactose or abnormal metabolic markers. Typical workflow: collection of neonatal blood spot by nursing, accessioning in the hospital laboratory, referral to the state newborn screening or a reference laboratory for 82776 testing, analytic measurement of GALT enzyme activity, result reporting to the ordering pediatrician or newborn screening program, and clinical follow-up if abnormal (dietary management and genetic counseling). Typical site of service: hospital newborn nursery, birthing center, or reference clinical laboratory. Typical patient scenario: a full-term neonate with feeding difficulty and borderline elevated galactose on initial newborn screen, prompting quantitative GALT enzyme assay from the dried blood spot prior to hospital discharge.

Coding Specifications

Modifier	Description	When to Use
`00`	Anesthesia: Other than general or regional	Not commonly applied to `82776`; not typical for newborn screening.

Taxonomy Code	Specialty	Notes
207Q00000X	Clinical Pathology	Common specialty for laboratory directors approving newborn metabolic testing.
207P00000X	Clinical Laboratory	Labs performing the assay and reporting results.
207L00000X	Molecular Biology Laboratory	Reference labs that perform specialized enzymatic or molecular confirmation.
2080P0001X	Pediatrics	Ordering clinicians in the newborn nursery or pediatric outpatient setting.
207RP1001X	Neonatal-Perinatal Medicine	Specialists involved when abnormal results require inpatient neonatal management.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E74.2`	Galactosemia	Primary diagnosis associated with deficient GALT enzyme activity; indicates biochemical confirmation or suspicion of galactose metabolism disorder.
`P59.9`	Neonatal jaundice, unspecified	Neonatal hyperbilirubinemia can be a presenting sign of galactosemia; commonly prompts metabolic evaluation including `82776`.
`P92.5`	Feeding problems of newborn	Poor feeding may be a presenting symptom that leads clinicians to order newborn metabolic screening and confirmatory testing.
`R63.3`	Feeding difficulties and mismanagement	Used when feeding issues prompt diagnostic metabolic evaluation.
`Z38.00`	Single liveborn infant, delivered in hospital, delivered vaginally	Encounter code for newborns undergoing routine newborn screening, where `82776` is commonly performed prior to discharge.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`83020`	Hemoglobin; glycosylated (A1C)	Not directly related; example of quantitative biochemical testing often performed in general chemistry labs alongside newborn screening assays when metabolic panels are run.
`82043`	Amino acids; qualitative or semiquantitative (e.g., chromatographic methods)	Performed in metabolic screening panels to evaluate amino acid disorders that may be assessed concurrently with galactosemia screening.
`82310`	Bilirubin; total	Neonatal labs often perform bilirubin testing when newborns have jaundice and when metabolic disorders like galactosemia are in the differential.
`83036`	Hemoglobin; electrophoresis (for sickle cell)	Part of newborn screening panels in many states; often processed alongside enzyme or metabolic assays.
`83912`	Galactose; blood, quantitative	A metabolic chemistry test that directly measures galactose levels and is frequently ordered with `82776` to evaluate suspected galactosemia.

OpenPayer

Summary & Overview